Clofarabine (Evoltra®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000461
English
Authors' recommendations:
Clofarabine (EvoltraR) is recommended for use within NHS Wales for the treatment of acute lymphoblastic leukaemic (ALL) in paediatric patients (. 21 yrs) who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Treatment is restricted to
patients in whom there is an intention to proceed to stem cell transplantation and who are under the care of a paediatric haemato-oncologist, as it is not cost effective when used for palliation. Its use will be audited and reviewed in 2009.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=85241&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Adenine Nucleotides
- Antineoplastic Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.